GSK PLC

ISIN: GB00BN7SWP63 WKN: BN7SWP6 Asset Class: Stock



Company Profile

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20:	22	202	21
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	18,644,000,000		20,769,000,000		18,674,000,000	
Common stock capital		1,348,000,000		1,347,000,000		1,347,000,000
Fixed assets	40,361,000,000		39,377,000,000		60,429,000,000	
Equity capital of a company		12,795,000,000		10,096,000,000		21,342,000,000
Cash and cash equivalents	2,936,000,000		3,723,000,000		4,274,000,000	
Accrued liabilities		2,835,000,000		3,111,000,000		3,743,000,000
Other assets	-		-		-	
Current liabilities		21,068,000,000		22,810,000,000		23,670,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		25,142,000,000		27,240,000,000		34,091,000,000
Different income		-		-		-
Other liabilities		6,791,000,000		6,805,000,000		6,220,000,000
Total assets	59,005,000,000	59,005,000,000	60,146,000,000	60,146,000,000	79,103,000,000	79,103,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	70,212	69,400	90,096
Equity ratio	20.75%	15.95%	34.93%
Debt-equity ratio	381.95%	526.91%	186.30%

Others

	2023	2022	2021
Tax Expense Rate	12.46%	12.56%	6.40%

GSK PLC

ISIN: GB00BN7SWP63 WKN: BN7SWP6 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	30,328,000,000	29,324,000,000	34,114,000,000
Net income	4,928,000,000	4,461,000,000	4,385,000,000
EBIT	7,901,038,200	7,469,268,400	7,170,171,800
Operating income before taxes	6,069,000,000	5,630,000,000	5,409,000,000
Cash Flow	6,348,000,000	6,625,000,000	7,202,000,000
Net interest income	-720,000,000	-788,000,000	-752,000,000
Research and development expenses	5,245,000,000	4,836,000,000	4,635,000,000
Income taxes	756,000,000	707,000,000	346,000,000
Result from investments in subsidaries, associates and other	-5,000,000	-2,000,000	33,000,000
Revenues per employee	502,702	491,747	440,662

Board of Directors	
Jonathan Symonds	Chairman of Supervisory Board
Anne Beal	Member of Supervisory Board
Hal Barron	Member of Supervisory Board
Harry Dietz	Member of Supervisory Board
Jeannie Lee	Member of Supervisory Board
Jesse Goodman	Member of Supervisory Board
Vishal Sikka	Member of Supervisory Board
Charles Bancroft	Member of Supervisory Board
Elizabeth Anderson	Member of Supervisory Board
Julie Brown	Member of Supervisory Board
Wendy Becker	Member of Supervisory Board

Members of Management Board			
Emma Walmsley	Chairman of Managing Board		
Anne-Marie Martin	Member of Executive Committee		
Christopher Corsico	Member of Executive Committee		
Tony Wood	Member of Executive Committee		
Amy Altshul	Member of Executive Committee		
Anita Kidgell	Member of Executive Committee		
Claire Lund	Member of Executive Committee		
David Redfern	Member of Executive Committee		
Diana Conrad	Member of Executive Committee		
Frannie DeFranco	Member of Executive Committee		
Graham Rivers	Member of Executive Committee		
James Ford	Member of Executive Committee		
Luke Miels	Member of Executive Committee		
María Cristina de Luna Basagoiti	Member of Executive Committee		
Maya Martinez-Davis	Member of Executive Committee		
Michael Elmore	Member of Executive Committee		
Mick Readey	Member of Executive Committee		
Philip Thomson	Member of Executive Committee		
Regis Jean-Pierre Simard	Member of Executive Committee		
Shobie Ramakrishnan	Member of Executive Committee		
Sonya Ghobrial	Member of Executive Committee		
Timothy Woodthorpe	Member of Executive Committee		
Victoria Whyte	Member of Executive Committee		